Abstract：
This study investigates the efficacy of modified Albizia procera gum as a release-retardant polymer in Diltiazem hydrochloride (DIL) matrix tablets. Carboxymethylated Albizia procera gum (CAP) and ionically crosslinked carboxymethylated Albizia procera gum (Ca-CAP) were utilized, with Ca-CAP synthesized via crosslinking CAP with calcium ions (Ca2+) using calcium chloride (CaCl2). Fourier Transform (FT) IR analysis affirmed polymer compatibility, while differential scanning calorimetry (DSC) and X-ray diffraction (XRD) assessed thermal behavior and crystallinity, respectively. Zeta potential analysis explored surface charge and electrostatic interactions, while rheology examined flow and viscoelastic properties. Swelling and erosion kinetics provided insights into water penetration and stability. CAP\'s carboxymethyl groups (-CH2-COO-) heightened divalent cation reactivity, and crosslinking with CaCl2 produced Ca-CAP through -CH2-COO- and Ca2+ interactions. Structural similarities between the polymers were revealed by FTIR, with slight differences. DSC indicated modified thermal behavior in Ca-CAP, while Zeta potential analysis showcased negative charges, with Ca-CAP exhibiting lower negativity. XRD highlighted increased crystallinity in Ca-CAP due to calcium crosslinking. Minimal impact on RBC properties was observed with both polymers compared to the positive control as water for injection (WFI). Ca-CAP exhibited improved viscosity, strength, controlled swelling, and erosion, allowing prolonged drug release compared to CAP. Stability studies confirmed consistent six-month drug release, emphasizing Ca-CAP\'s potential as a stable, sustained drug delivery system over CAP. Robustness and accelerated stability tests supported these findings, underscoring the promise of Ca-CAP in controlled drug release applications.
摘要：
这项研究调查了改性的Albiziaprocera胶作为盐酸地尔硫（DIL）基质片剂中的缓释聚合物的功效。使用了羧甲基化Albiziaprocera胶（CAP）和离子交联的羧甲基化Albiziaprocera胶（Ca-CAP），通过使用氯化钙（CaCl2）将CAP与钙离子（Ca2）交联合成Ca-CAP。FTIR剖析肯定了聚合物的相容性，而差示扫描量热法（DSC）和X射线衍射（XRD）评估热行为和结晶度，分别。Zeta电位分析探索了表面电荷和静电相互作用，而流变学检查流动和粘弹性。膨胀和侵蚀动力学提供了对水渗透和稳定性的见解。CAP的羧甲基基团（-CH2-COO-）提高了二价阳离子反应性，与CaCl2交联通过-CH2-COO-和Ca2相互作用产生Ca-CAP。FTIR揭示了聚合物之间的结构相似性，略有不同。DSC表明在Ca-CAP中改性的热行为，而Zeta电位分析显示负电荷，Ca-CAP表现出较低的负性。XRD强调了由于钙交联而在Ca-CAP中增加的结晶度。与作为注射用水(WFI)的阳性对照相比,用两种聚合物观察到对RBC性质的最小影响。Ca-CAP表现出改善的粘度，力量,控制肿胀，和侵蚀，与CAP相比，可以延长药物释放时间。稳定性研究证实持续六个月的药物释放，强调Ca-CAP的潜力是稳定的，持续给药系统超过CAP。鲁棒性和加速稳定性测试支持这些发现，强调Ca-CAP在药物控释应用中的前景。
